Emeryville, CA, United States of America

Solomon Stonebloom

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Solomon Stonebloom: Innovator in Synthetic Particle Technology**

Introduction

Solomon Stonebloom is an accomplished inventor based in Emeryville, California. With a focus on the development of innovative synthetic particles, he has made significant strides in the field of immunology. His work is notable for its potential applications in immune cell activation, which could pave the way for advancements in medical therapies.

Latest Patents

Stonebloom holds a patent for "Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation." This patent describes a hydrogel particle that contains a matrix made up of polymerized monomers, featuring a range of micropores and macropores. The particle incorporates immunostimulatory biomolecules such as anti-CD3 and anti-CD28 antibodies, which play a critical role in enhancing immune responses.

Career Highlights

Currently, Solomon Stonebloom is employed at Slingshot Biosciences, Inc., where he continues to push the boundaries of synthetic biology. His dedication to innovation in this area showcases his commitment to harnessing technology for better health outcomes.

Collaborations

Stonebloom collaborates with talented individuals like Daixuan Zhang and Juan Armas, enhancing the creativity and technical expertise available within his team. This collaborative environment has been essential for the development and refinement of their collective projects.

Conclusion

With his innovative approach to synthetic particles, Solomon Stonebloom is making significant contributions to the fields of biology and medicine. His work not only exemplifies the spirit of innovation but also underscores the importance of collaboration in driving scientific advancements forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…